Crossmark

Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects

Crossref DOI link: https://doi.org/10.1007/s00280-018-3750-1

Published Online: 2018-12-11

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yuen, Eunice https://orcid.org/0000-0003-2145-6368
Posada, Maria

Smith, Claire

Thorn, Katharine

Greenwood, Dale

Burgess, Michelle

A. Benhadji, Karim

Ortega, Demetrio

Chinchen, Louise

Suico, Jeffrey
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2018-12-11
More Information

Article History

Received: 29 August 2018

Accepted: 3 December 2018

First Online: 11 December 2018

Compliance with ethical standards

:

: All authors are employees of Eli Lilly and Company.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below